¼¼°èÀÇ °ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ½ÃÀå
Air Compressor Nebulizers
»óǰÄÚµå : 1737488
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,015,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,045,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

°ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ¼¼°è ½ÃÀåÀº 2030³â±îÁö 13¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 9¾ï 730¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â °ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£¿¡ CAGR 5.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 13¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÈÞ´ëÇü ³×ºê¶óÀÌÀÚ´Â CAGR 4.9%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 8¾ï 2,370¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ź»óÇü ³×ºæ¶óÀÌÀú ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 7.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2¾ï 4,720¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ °ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ½ÃÀåÀº 2024³â¿¡ 2¾ï 4,720¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â ºÐ¼® ±â°£¿¡¼­ CAGR 9.1%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 2¾ï 5,630¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 2.9%¿Í 5.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è °ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

°ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú°¡ È£Èí±â ¾à¹° Àü´Þ¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

°ø±â ¾ÐÃà±â ºÐ¹«±â´Â ³ôÀº ½Å·Ú¼º, ºñ¿ë È¿À²¼º, ¸¸¼º ¹× ±Þ¼º Æó ÁúȯÀÇ ¾à¹° Àü´Þ¿¡ ´ëÇÑ ÀûÀÀ¼ºÀ¸·Î ÀÎÇØ È£Èí±â Ä¡·á¿¡¼­ Áß¿äÇÑ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. Á¡¼º ¶Ç´Â ÇöŹ¾× ±â¹Ý ¾à¹°ÀÇ ÇѰ谡 ÀÖ´Â ÃÊÀ½ÆÄ ºÐ¹«±â³ª ¸Þ½¬ ºÐ¹«±â¿Í ´Þ¸®, ¾ÐÃà±â ±¸µ¿ ½Ã½ºÅÛÀº ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å, ±â°üÁö È®ÀåÁ¦, Á¡¾× ¿ëÇØÁ¦, Ç×»ýÁ¦ µî ´Ù¾çÇÑ Á¦Á¦¸¦ ¿¡¾î·ÎÁ¹È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ´Ù¿ëµµ¼ºÀ¸·Î ÀÎÇØ õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ³¶Æ÷¼º ¼¶À¯Áõ, ±â°üÁö¿° µî ´Ù¾çÇÑ È¯ÀÚ±º¿¡ °ÉÃÄ Ãµ½Ä Ä¡·á¿¡ ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ È¯°æÀ̳ª ÀçÅÃÄ¡·á ȯ°æ¿¡¼­ ¾ÐÃà½Ä ºÐ¹«±â´Â ÃÖ¼ÒÇÑÀÇ Á¶ÀÛ º¹À⼺À¸·Î Áß´Ü ¾ø´Â Ä¡·á¸¦ º¸ÀåÇÏ´Â °ß°íÇϰí À¯Áöº¸¼ö°¡ ÀûÀº ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¾ÐÃà °ø±âÀÇ ÀϰüµÈ È帧À» »ý¼ºÇÏ°í ¾×ü ¾à¹°À» ÈíÀÔ °¡´ÉÇÑ ¹Ì½ºÆ®·Î º¯È¯ÇÏ´Â ±â°èÀû ¼³°è´Â º¹¾à ¼øÀÀµµ¿Í º¹¿ë·® Àϰü¼ºÀÌ °¡Àå Áß¿äÇÑ Àå½Ã°£ Ä¡·á¿¡ ÀÌ»óÀûÀÔ´Ï´Ù.

¶ÇÇÑ, ȯÀÚ°¡ ÈíÀԱ⠻ç¿ë¿¡ ÇÊ¿äÇÑ Á¶Á¤À» ¾î·Á¿öÇÏ´Â ¼Ò¾Æ ¹× ³ëÀÎ ÀÇ·á¿¡¼­ °ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú´Â ´õ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ´Â Àü´Þ ½Ã½ºÅÛÀ¸·Î¼­ À¯¿ëÇÕ´Ï´Ù. ¼öµ¿ ÈíÀÔÀÌ °¡´ÉÇϱ⠶§¹®¿¡ »ç¿ëÀÚ´Â Á¤»óÀûÀΠȣÈíÀ» ÅëÇØ ¾à¹°À» Åõ¿©¹ÞÀ» ¼ö ÀÖ¾î º´µ¿, ³ëÀÎ ¿ä¾ç¿ø, ÀçÅà Æó ÀçȰ ÇÁ·Î±×·¥¿¡¼­ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. °í±Þ ´ëüǰ¿¡ ºñÇØ °¡°ÝÀÌ Àú·ÅÇϱ⠶§¹®¿¡ ±¤¹üÀ§ÇÑ È£Èí±â Áúȯ °ü¸®¸¦ ¸ñÇ¥·Î ÇÏ´Â °øÁߺ¸°Ç ÇÁ·Î±×·¥¿¡ È®Àå °¡´ÉÇÑ ´ë¾ÈÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. °í·ÉÈ­, µµ½Ã ´ë±â ¿À¿°, Á÷¾÷Àû ³ëÃâ, Èí¿¬°ú °ü·ÃµÈ Æó Áúȯ µîÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ¸¸¼º È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ³»±¸¼ºÀÌ ¶Ù¾î³­ °í¼º´É ¾ÐÃà½Ä ºÐ¹«±â¿¡ ´ëÇÑ ¼ö¿ä°¡ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀº ´Ù¾çÇÑ ¾à¹°°úÀÇ È£È¯¼º, ¾ÈÁ¤ÀûÀÎ ¿¡¾î·ÎÁ¹ Ãâ·Â, ¼ö½Ê³âµ¿¾È »ç¿ëÇϸ鼭 ÀÔÁõµÈ ÀÓ»óÀû È¿°ú·Î ÀÎÇØ ¾ÐÃà½Ä ºÐ¹«±â¸¦ ¼±È£Çϰí ÀÖ½À´Ï´Ù.

Á¦Ç°ÀÇ ÁøÈ­´Â È޴뼺, »ç¿ëÀÚ ÆíÀǼº, ½º¸¶Æ® ±â´É¿¡ ¾î¶»°Ô ´ëÀÀÇϰí Àִ°¡?

Á¦Á¶¾÷üµéÀº °ø±â ¾ÐÃà±â ºÐ¹«±â¸¦ º¸´Ù ÈÞ´ëÇϱ⠽±°í, »ç¿ëÇϱ⠽±°í, Ȱµ¿ÀûÀÎ ¶óÀÌÇÁ ½ºÅ¸ÀÏ¿¡ ÀûÇÕÇϵµ·Ï ¼ÒÇüÈ­ ¹× ÀÎü°øÇÐÀû Àç¼³°è¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ºÎÇǰ¡ Å« ÀåÄ¡´Â ¼ÒÀ½ °¨¼Ò ±â¼ú, Çâ»óµÈ ±â·ù Á¶Àý, ´õ ºü¸¥ ºÐ¹« Áֱ⸦ °®Ãá ¼ÒÇü Ź»ó¿ë ¹× ÇÚµå Çïµå À¯ÇüÀ¸·Î ´ëüµÇ¾ú½À´Ï´Ù. ³»ÀåÇü ¾×¼¼¼­¸® º¸°üÇÔ, ¾î¸°ÀÌ¿ë ÀÎÅÍÆäÀ̽º, ´Ù¾çÇÑ ¿¬·É´ë¸¦ À§ÇÑ ÅëÇÕÇü ¸¶½ºÅ© µîÀÇ Çõ½ÅÀ¸·Î °¡Á¤, ¿©Çà ȯ°æ ¹× ¿Ü·¡ Áø·á¿¡¼­ ÀÏ»óÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â ½Ç¿ë¼ºÀ» °®Ãß°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ¼Ò¾Æ ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í, ÀÚÁÖ ¾ÇÈ­µÇ´Â ȯÀÚÀÇ À̵¿½Ä È£Èí °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â µ¥ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, °¡º±°í ¹èÅ͸®·Î ±¸µ¿µÇ´Â ÄÄÇÁ·¹¼­·ÎÀÇ ÀüȯÀº ³óÃÌ Áö¿ª°ú À̵¿ Áø·á¼Ò¿¡¼­ ¿ø°Ý ÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

µ¿½Ã¿¡, º¸´Ù ±¤¹üÀ§ÇÑ µðÁöÅÐ °Ç°­ Æ®·»µå¿¡ ¸ÂÃß¾î ÃֽоÐÃà±â ºÐ¹«±â¿¡ ¿¬°á ±â´ÉÀÌ ÅëÇյǰí ÀÖÀ¸¸ç, ºí·çÅõ½º ¹× Wi-Fi ±â´ÉÀ» °®Ãá ±â±â´Â »ç¿ë µ¥ÀÌÅÍ ÃßÀû, Åõ¾à ÀÏÁ¤ ¾Ë¸², ÀÇ·áÁø°ú Ä¡·á ±â·ÏÀÇ ¿ø°Ý °øÀ¯¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÇöÀç ÀϺΠ¸ðµ¨Àº ½º¸¶Æ®Æù ¾Û°ú ȣȯµÇ¾î »ç¿ëÀÚ³ª °£º´ÀÎÀÌ ºÐ¹«±â ÈíÀÔ ¼¼¼ÇÀ» ¸ð´ÏÅ͸µÇϰí, º¹¿ë·® ¾Ë¸²À» ¹Þ°í, Ä¡·á ±â·ÏÀ» ÀúÀåÇÒ ¼ö ÀÖ´Â ±â´ÉÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½º¸¶Æ®ÇÑ ±â´ÉÀº COPD³ª õ½Ä°ú °°Àº ¸¸¼º Áúȯ °ü¸®¿¡ ƯÈ÷ À¯¿ëÇϸç, ÀæÀº ¿ë·® ¸ð´ÏÅ͸µ°ú ÀÇ»çÀÇ Çǵå¹éÀ» ÅëÇØ Áúº´ °á°ú¸¦ Å©°Ô °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÄÄÇÁ·¹¼­ ±â¼úÀÇ Çâ»óÀ¸·Î ÀÛµ¿ Áß ¹ß¿­°ú Áøµ¿ÀÌ °¨¼ÒÇÏ¿© Àå½Ã°£ »ç¿ë ½Ã Æí¾ÈÇÔ°ú ¾ÈÀü¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç° °­È­ÀÇ À¶ÇÕÀº ½ÅÈï±¹ ½ÃÀå°ú °³Ã´µÈ ÇコÄÉ¾î ½ÃÀå ¸ðµÎ¿¡¼­ °ø±â ¾ÐÃà±â ºÐ¹«±âÀÇ ¸Å·Âµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù.

¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â Àå¼Ò¿Í ÀÌ¿ë »ç·Ê´Â?

°ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú¿¡ ´ëÇÑ ¼ö¿ä´Â ¸¸¼º È£Èí±â ÁúȯÀÇ Áø´Ü Áõ°¡¿Í Àü ¼¼°è °í·ÉÈ­·Î ÀÎÇØ ½Ã¼³ ¹× Àç°¡ °£È£ ¸ðµÎ¿¡¼­ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. º´¿ø ȯ°æ¿¡¼­´Â ÀÀ±Þ½Ç, ÁßȯÀÚ½Ç, ¼ö¼ú ÈÄ È£Èí ȸº¹½Ç µî Áï°¢ÀûÀÎ ¾à¹° Àü´Þ°ú »ç¿ë ÆíÀǼºÀÌ ÇʼöÀûÀÎ °÷¿¡¼­ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÁßÁõ õ½Ä ¹ßÀÛ, Çϱ⵵ °¨¿°, ÀΰøÈ£Èí±â °ü·Ã ÇÕº´Áõ µî ±Þ¼º Áõ»óÀÇ Ä¡·á¿¡ Àû¿ëµÇ¾î È£Èí±â º´µ¿ÀÇ ÇʼöǰÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²², ¿Ü·¡ Áø·á¼Ò ¹× 1Â÷ Áø·á¼Ò¿¡¼­´Â ƯÈ÷ °í±Þ ÈíÀÔ ½Ã½ºÅÛÀ» ±¸ÀÔÇÒ ¿©·ÂÀÌ ¾ø´Â ºñº¸Çè ȯÀÚ¸¦ ´ë»óÀ¸·Î ¿Ü·¡ È£Èí±â Áö¿ø ¹× Áö¼ÓÀûÀÎ Áúº´ °ü¸®¸¦ À§ÇØ ¾ÐÃà±â½Ä ºÐ¹«±â¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù.

ÀçÅÃÄ¡·á ºÐ¾ß´Â °ø±â ¾ÐÃà±â ºÐ¹«±â¸¦ °¡Àå ºü¸£°Ô äÅÃÇϰí ÀÖ´Â ºÐ¾ß Áß ÇϳªÀ̸ç, COPD, Æó¼¶À¯Áõ, Àå±âÀûÀÎ COVID °ü·Ã È£Èí±â ÈÄÀ¯Áõ°ú °°Àº ¸¸¼º ÁúȯÀ» °ü¸®Çϴ ȯÀÚµéÀº º´¿ø ¹æ¹®À» ÁÙÀ̰í Àû±ØÀûÀ¸·Î Áõ»óÀ» °ü¸®Çϱâ À§ÇØ Á¡Á¡ ´õ ¸¹Àº ÀçÅà ºÐ¹« ¿ä¹ýÀ» ó¹æ¹Þ°í ÀÖ½À´Ï´Ù. ó¹æÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ºÐ»êÇü Ä¡·á¿Í ¿ø°Ý ȯÀÚ °ü¸®¸¦ °­Á¶ÇÏ´Â Æ÷½ºÆ® ÆÒµ¥¹Í ÀÇ·á ¸ðµ¨¿¡¼­ ƯÈ÷ Áß¿äÇÏ°Ô ¿©°ÜÁö´Â ºÎºÐÀÔ´Ï´Ù. ¶ÇÇÑ, °ø±â ¾ÐÃà±â ºÐ¹«±â´Â ¼öÀÇÇÐ, ƯÈ÷ ¼Òµ¿¹°ÀÇ È£Èí±â °¨¿° ¹× õ½Ä À¯»ç Áõ»óÀÇ Ä¡·á¿¡ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼Ò¾Æ°ú ÀÇ»ç¿Í ³ëÀÎÀÇÇÐ Àü¹®Àǵ鵵 ºÐ¹«±â¸¦ ÀÌ¿ëÇÑ Ä¡·á¹ý ó¹æÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº Ãë¾à °èÃþ¿¡°Ô ´õ ¾ÈÀüÇÏ°í ½±°Ô Åõ¿©ÇÒ ¼ö ÀÖ´Â ´ëü ¿ä¹ýÀ» Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù. ÀÇ·á º¸Çè»çµéÀÌ °¡Á¤¿ë ºÐ¹«±â¿Í °ü·Ã ¼Ò¸ðǰ¿¡ ´ëÇÑ º¸Çè Àû¿ëÀ» ½ÃÀÛÇϸ鼭 ¼Òµæ ¼öÁØÀ» ³Ñ¾î ½ÃÀå Á¢±Ù¼ºÀÌ °³¼±µÇ¾î ¼º¼÷ÇÑ ½ÃÀå°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼­ º¸±ÞÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

°ø±â ¾ÐÃà±â ¹× ºÐ¹«±â ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

°ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°èÀûÀ¸·Î ¸¸¼º È£Èí±â Áúȯ Áõ°¡, ÀçÅÃÄ¡·á¿¡ ´ëÇÑ °ü½É Áõ°¡, Áö¼ÓÀûÀÎ Á¦Ç° Çõ½Å¿¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ °í·ÉÈ­ »çȸ¿Í ´ë±â ÁúÀÌ ¾ÇÈ­µÇ´Â µµ½Ã Áö¿ª¿¡¼­ COPD, õ½Ä, ±â°üÁöÈ®ÀåÁõ ȯÀÚ°¡ ±ÞÁõÇÏ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº Àå±âÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾à¹° Àü´Þ ½Ã½ºÅÛÀÌ ÇÊ¿äÇϸç, ¾ÐÃà±â ºÐ¹«±â´Â Áö¼ÓÀûÀÎ Ä¡·á¸¦ À§ÇÑ °ËÁõµÈ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¿Ü·¡ ȯÀÚ ¹× ÀçÅà ġ·á ¸ðµ¨·ÎÀÇ ÀüȯÀ¸·Î ÀÎÇØ ÈÞ´ë°¡ °£ÆíÇÏ°í »ç¿ëÇϱ⠽¬¿î È£Èí±â Ä¡·á Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀº °íÀ§Ç豺 ¹× ºñÇùÁ¶ÀûÀΠȯÀÚ±º¿¡ ´ëÇØ ÈíÀԱ⺸´Ù ¾ÈÀüÇÏ°í ¼øÀÀµµ°¡ ³ôÀº ºÐ¹«±â¸¦ Àû±ØÀûÀ¸·Î È«º¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®»êÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¼ºÀå ¿äÀÎÀº ÆíÀǼº, ¿¬°á¼º, ¼º´É¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ±â´ë¿¡ ºÎÇÕÇÏ´Â Á¦Ç° °³¼±ÀÇ ¹°°áÀÔ´Ï´Ù. Àú¼ÒÀ½, ÀÎü°øÇÐÀû µðÀÚÀÎ, ´õ ºü¸¥ ¿¡¾î·ÎÁ¹È­ ¹× ½º¸¶Æ® ¸ð´ÏÅ͸µ ±â´ÉÀÇ °³¹ß·Î ÀÎÇØ ÀÌ·¯ÇÑ ±â±â´Â ÷´Ü ±â¼ú¿¡ ¹Î°¨ÇÑ ¼ÒºñÀÚ¿Í °£º´Àο¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡°¥ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼±Áø±¹°ú ½ÅÈï±¹ ¸ðµÎ¿¡¼­ Á¤ºÎ ÀÇ·á Á¦µµ¿Í º¸Çè ȯ±ÞÀ» ÅëÇØ °¡°Ý ¹× Á¢±Ù¼ºÀÌ °³¼±µÇ°í ÀÖÀ¸¸ç, ¿¹¹æÀû È£Èí±â °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â Áø´Ü ¹× Áõ»ó ¹ßÇö ÀüÀÇ »ç¿ëÀÚµé »çÀÌ¿¡¼­ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ÐÃà½Ä ºÐ¹«±â¸¦ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ÇÁ·Î±×·¥ ¹× ¿ø°Ý ÀÇ·á ¼­ºñ½º¿¡ Àü·«ÀûÀ¸·Î ÅëÇÕÇÔÀ¸·Î½á ¾ÐÃà½Ä ºÐ¹«±â´Â Çö´ë ÀÇ·á ¼­ºñ½º Á¦°ø¿¡ ÀÖ¾î °ü·Ã¼ºÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÇÇÐÀû, Àα¸Åë°èÇÐÀû, ±â¼úÀû ¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼¼°è °ø±â¾ÐÃà±â ³×ºæ¶óÀÌÀú ½ÃÀåÀÇ ²ÙÁØÇÑ Çõ½Å ÁÖµµÀû ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

È޴뼺(ÈÞ´ëÇü, Ź»óÇü);Á¦Ç° À¯Çü(°ø±â¾Ð½Ä ³×ºæ¶óÀÌÀú, ÃÊÀ½ÆÄ½Ä ³×ºæ¶óÀÌÀú, ¸Þ½Ã½Ä ³×ºæ¶óÀÌÀú, È£Èí ÀÛµ¿½Ä ³×ºæ¶óÀÌÀú, ±âŸ Á¦Ç° À¯Çü);ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¹× Ŭ¸®´Ð, ÀçÅà ÇコÄɾî, Áø´Ü½ÇÇè½Ç, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 42°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ÀÇ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Air Compressor Nebulizers Market to Reach US$1.3 Billion by 2030

The global market for Air Compressor Nebulizers estimated at US$907.3 Million in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Portable Nebulizers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$823.7 Million by the end of the analysis period. Growth in the Tabletop Nebulizers segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$247.2 Million While China is Forecast to Grow at 9.1% CAGR

The Air Compressor Nebulizers market in the U.S. is estimated at US$247.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$256.3 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Air Compressor Nebulizers Market - Key Trends & Drivers Summarized

Why Are Air Compressor Nebulizers Remaining Indispensable in Respiratory Drug Delivery?

Air compressor nebulizers continue to hold a critical position in respiratory therapy due to their high reliability, cost-effectiveness, and adaptability in delivering medications for chronic and acute pulmonary conditions. Unlike ultrasonic or mesh nebulizers that may face limitations with viscous or suspension-based drugs, compressor-driven systems are capable of aerosolizing a broad range of formulations, including corticosteroids, bronchodilators, mucolytics, and antibiotics. This versatility makes them a preferred choice for the treatment of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchitis across varied patient demographics. Particularly in low-resource settings and homecare environments, compressor nebulizers offer a robust and low-maintenance solution that ensures uninterrupted therapy with minimal operational complexity. Their mechanical design, which generates a consistent stream of compressed air to convert liquid medication into an inhalable mist, is ideal for long-duration treatments where medication adherence and dosage consistency are paramount.

Furthermore, in pediatric and geriatric care-where patients may struggle with the coordination required in inhaler use-air compressor nebulizers serve as a more accessible delivery system. They enable passive inhalation, allowing users to receive medication through normal breathing, which is particularly valuable in hospital wards, eldercare facilities, and home-based pulmonary rehabilitation programs. The affordability of these devices compared to high-end alternatives also makes them a scalable option for public health programs targeting widespread respiratory disease management. The growing prevalence of chronic respiratory conditions globally, driven by aging populations, urban air pollution, occupational exposures, and smoking-related lung disorders, continues to support demand for durable, high-performance compressor nebulizers. Additionally, healthcare providers prefer them for their compatibility with a wide array of drug types, consistent aerosol output, and proven clinical efficacy over decades of use.

How Is Product Evolution Addressing Portability, User Comfort, and Smart Features?

Manufacturers are investing in miniaturization and ergonomic redesigns to make air compressor nebulizers more portable, user-friendly, and suitable for active lifestyles. Traditional bulky units are being replaced by compact tabletop and handheld models with noise-reduction technology, improved airflow regulation, and faster nebulization cycles. Innovations such as built-in storage for accessories, child-friendly interfaces, and integrated masks for different age groups are making these devices more practical for routine use in households, travel settings, and outpatient care. These advancements are particularly critical for improving compliance among pediatric patients and enabling mobile respiratory care for those with frequent exacerbations. Additionally, the shift toward lightweight, battery-powered compressors is supporting remote healthcare delivery in rural and mobile healthcare units.

Simultaneously, connectivity features are being integrated into modern compressor nebulizers to align with broader digital health trends. Devices with Bluetooth or Wi-Fi capability are enabling usage data tracking, medication schedule alerts, and remote sharing of therapy logs with healthcare providers. Some models are now compatible with smartphone apps that allow users or caregivers to monitor nebulization sessions, receive dosage reminders, and store treatment history-improving medication adherence and personalized care. These smart features are particularly beneficial in managing chronic conditions like COPD and asthma, where frequent dose monitoring and physician feedback can significantly improve disease outcomes. Additionally, improvements in compressor technology are reducing heat buildup and vibration during operation, enhancing comfort and safety during extended use. The convergence of these product enhancements is broadening the appeal of air compressor nebulizers across both emerging and developed healthcare markets.

Where Is Demand Rising and Which Use Cases Are Gaining Ground?

The demand for air compressor nebulizers is expanding rapidly across both institutional and homecare settings, driven by rising diagnoses of chronic respiratory conditions and the aging global population. In hospital environments, these devices are being increasingly used in emergency departments, ICUs, and post-operative respiratory recovery units where fast-acting drug delivery and ease of use are essential. Their application in treating acute conditions such as severe asthma attacks, lower respiratory tract infections, and ventilator-associated complications continues to make them a staple in respiratory wards. In parallel, outpatient clinics and primary care centers are adopting compressor nebulizers for walk-in respiratory support and ongoing disease management, especially for underinsured patients who cannot afford more sophisticated inhalation systems.

The home healthcare segment represents one of the fastest-growing avenues for air compressor nebulizer adoption. Patients managing chronic diseases like COPD, pulmonary fibrosis, and long COVID-related respiratory sequelae are increasingly prescribed at-home nebulization therapy to reduce hospital visits and manage symptoms proactively. This is especially relevant in the post-pandemic healthcare model that emphasizes decentralized care and remote patient management. Additionally, air compressor nebulizers are gaining application in veterinary medicine, particularly for treating respiratory infections and asthma-like conditions in small animals. Pediatricians and geriatricians are also expanding their prescription of nebulizer-based therapies as these systems offer safer, easier-to-administer alternatives for vulnerable populations. With health insurers now offering coverage for home-use nebulizers and associated consumables, market access is improving across income levels, further boosting uptake in both mature and emerging markets.

The Growth in the Air Compressor Nebulizers Market Is Driven by Several Factors…

It is anchored in the rising global burden of chronic respiratory diseases, increased focus on home-based healthcare, and ongoing product innovation. A primary driver is the surge in COPD, asthma, and bronchiectasis cases, particularly in aging populations and urban environments with deteriorating air quality. These conditions necessitate long-term, reliable drug delivery systems, and compressor nebulizers offer a proven solution for continuous care. Additionally, the increasing shift toward outpatient and at-home treatment models is creating sustained demand for portable, easy-to-use respiratory therapy devices. Healthcare systems are actively promoting nebulization as a safer, more compliant alternative to inhalers for high-risk and low-coordination patient groups, thereby reinforcing market adoption.

Another significant growth enabler is the wave of product improvements that align with consumer expectations for convenience, connectivity, and performance. The development of low-noise, ergonomic designs, coupled with faster aerosolization and smart monitoring capabilities, is making these devices more attractive to tech-aware consumers and caregivers. Government health schemes and insurance reimbursements in both developed and developing countries are improving affordability and access, while increased awareness of preventive respiratory care is expanding the market among early-diagnosed and pre-symptomatic users. Furthermore, the strategic integration of compressor nebulizers into remote patient monitoring (RPM) programs and telehealth services is boosting their relevance in modern healthcare delivery. These combined medical, demographic, and technological factors are underpinning a steady, innovation-led expansion in the global air compressor nebulizers market.

SCOPE OF STUDY:

The report analyzes the Air Compressor Nebulizers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Portability (Portable, Tabletop); Product Type (Pneumatic Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Breath-Actuated Nebulizers, Other Product Types); End-User (Hospitals & Clinics, Home Healthcare Settings, Diagnostic Laboratories, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â